echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Front Immunol: A retrospective study of the replacement and immunomodulatory activity of 20% subcutaneous immunoglobulin in patients with autoimmune myositis and CVID

    Front Immunol: A retrospective study of the replacement and immunomodulatory activity of 20% subcutaneous immunoglobulin in patients with autoimmune myositis and CVID

    • Last Update: 2022-03-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Immunoglobulin (Ig) replacement therapy is a life-saving therapy for primary antibody deficiency
    .


    The introduction of subcutaneous immunoglobulin (SCIg) has greatly improved the quality of life of patients compared to traditional intravenous administration


    This study aimed to increase knowledge on the anti-inflammatory and immunomodulatory effects of SCIg in the treatment of myositis
    .


    To this end, the efficacy of 20% human SCIg therapy (20% SCIg, Hizentra®, CSL Behring) was long-term assessed in PM/DM patients cared for at our center


    Results support the beneficial effect and tolerability of 20% SCIg long-term treatment in PM/DM patients, reporting creatine kinase levels, muscle strength, skin condition, dysphagia, disease activity (MITAX score), and disability (HAQ-DI score) Significant improvement
    .


    No systemic reactions were reported in any of the patients


    This study suggests that 20% SCIg in the treatment of PM/DM is a safe and feasible treatment, an effective alternative to IVIg, and has important advantages in improving the quality of life of patients


    Source: Danieli MG, Verga JU, Mezzanotte C, et al.


    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.